Press Releases Kuros Biosciences AG

Equities

KURN

CH0325814116

Market Closed - Swiss Exchange Other stock markets 16:31:10 10/05/2024 BST			5-day change	1st Jan Change
7.15 ^CHF	+8.33%		+7.20%	+104.87%

04-24	Kuros Biosciences Posts Higher Q1 Product Sales	MT
04-17	Kuros Biosciences AG Approves Board of Director and Committee Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales	04-24	EQ
Annual General Meeting of Kuros Biosciences approves all resolutions	04-17	EQ
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023	03-13	EQ
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update	03-08	EQ
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference	02-01	EQ
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand	01-31	EQ
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	01-04	EQ
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA	12-27	EQ
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages	11-28	EQ
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management	12/10/23	EQ
Kuros Biosciences : Reports Results for First Half 2023	31/08/23	PU
Kuros Biosciences : Investor Webcast Presentation, H1 2023	23/08/23	PU
Kuros Biosciences "doing extremely well" in innovative spinal fusion treatments	11/08/23	AQ
Kuros Biosciences : Investor Presentation, 2023	09/08/23	PU
Kuros Biosciences Reports Results for First Half 2023	09/08/23	EQ
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial	13/07/23	EQ
Kuros Biosciences : Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial	13/07/23	PU
Annual General Meeting of Kuros Biosciences approves all resolutions	08/05/23	EQ
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023	27/04/23	EQ
Kuros Biosciences : Investor Presentation 2022	19/03/23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kuros Biosciences AG

Equities

KURN

CH0325814116

Press Releases

Filters